ישראל - עברית - Ministry of Health

novartis israel ltd - timolol as maleate; travoprost - תמיסה לעין - travoprost 40 mcg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intraocular pressure (iop) in patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

ישראל - עברית - Ministry of Health

novartis israel ltd - budesonide - קפסולות - budesonide 200 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - vinorelbine as tartrate - קפסולות - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine - for the treatment of non small cell lung cancer. for the treatment of advanced breast cancer.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

ישראל - עברית - Ministry of Health

bayer israel ltd - larotrectinib as sulfate - תמיסה (פומי) - larotrectinib as sulfate 20 mg/ml - larotrectinib

ישראל - עברית - Ministry of Health

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

ישראל - עברית - Ministry of Health

inovamed ltd - bicalutamide - טבליות מצופות פילם - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable